Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma
Open Access
- 25 July 2026
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70558
Abstract
Background: While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood. Objectives: To characterise metastatic dissemination patterns and tumour burden in NB, evaluate their response to induction therapy, and determine their prognostic impact. Methods: We retrospectively analysed 53 patients with metastatic NB between 2010 and 2024 in a reference tertiary care hospital and treated as per SIOPEN protocol or standard‐of‐care recommendations. Responses were recorded as per INRC 2017. Survival was estimated using Kaplan–Meier analysis, and associations between metastatic patterns and outcomes were evaluated by univariate analysis. Results: The most frequent metastatic sites were bone (77%), regional lymph nodes (64%), and bone marrow (55%). MSI (metastatic site index) was 1 ( n = 13), 2 ( n = 13), 3 ( n = 15), or ≥4 ( n = 12). Overall response according to INRC after induction therapy achieved complete ( n = 1), partial ( n = 41), minor ( n = 6) responses, stable ( n = 4) or progressive disease ( n = 1). Regarding metastatic response, regional and distant lymph nodes, renal and pulmonary decreased in size by 66%, 85%, 90 and 99%, respectively. The median SIOPEN score decreased from 16.5 to 0. Bone marrow infiltration disappeared in 82%. High tumour burden strongly correlated with poor outcomes. Conclusions: Presence of renal metastases, ascites, bone marrow infiltration, high tumour burden at diagnosis and post‐induction pulmonary or renal metastases are negative prognostic markers. Incorporating these factors into risk stratification may guide personalised treatment strategies. Future work should elucidate the genomic background and underlying causes of these different metastatic patterns.Keywords
This publication has 17 references indexed in Scilit:
- The Prognostic Value of MIBG Metastatic Patterns in Pediatric Patients with High-Risk Stage 4 Neuroblastoma Following Induction TherapyAcademic Radiology, 2026
- Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology GroupEJC Paediatric Oncology, 2024
- NeuroblastomaPediatric Blood & Cancer, 2021
- Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)European Journal of Cancer, 2019
- Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseEuropean Journal of Cancer, 2016
- Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectCancer, 2015
- The molecular genetic profile of neuroblastomaDiagnostic Histopathology, 2014
- NeuroblastomaThe Lancet, 2007